A Study to Investigate the Effect of 7-Keto on Resting Metabolic Rate in Overweight Adults

Phase 2

Completed

• Conditions: Resting Metabolic Rate; Overweight Subjects
• Interventions: Dietary Supplement: 7-Keto 25mg; Dietary Supplement: Placebo; Dietary Supplement: 7-Keto 50mg

• Registration Number: NCT04782024
• Lead Sponsor: KGK Science Inc.

Brief Summary

This study will investigate the effect of two different doses of 7-Keto compared to placebo on resting metabolic rate. One third of subjects will be given the lower 7-Keto dose, one third will be given the higher 7-Keto dose and one third will be given the placebo.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-09-30
• Primary Completion: 2016-11-04
• Study Completion: 2016-11-04
• Study First Submitted: 2021-03-01
• Study First Submitted QC: 2021-03-01
• Study First Posted: 2021-03-04
• Status Verified: 2021-04
• Last Update Submitted: 2021-04-22
• Last Update Posted: 2021-04-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 138

Inclusion Criteria

1. Male or female 20 to 55 years of age

2. If female, subject is not of child bearing potential. Defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation).

   OR

   Female subject of childbearing potential must agree to use a medically approved method of non-hormonal birth control and have a negative urine pregnancy test result. Birth Control methods must be initiated at least 14 days prior to randomization and must be continued until 28 days after the end of study visit. Acceptable methods of birth control include:

   • Double barrier method
   • Intrauterine devices (non-hormonal)
   • Cervical caps or sponges
   • Use of male/female condom
   • Vasectomy of partner
   • Non-heterosexual lifestyle

3. If female and currently experiencing menstrual cycles, subjects should have regular menstrual cycles (28 ± 2 days) and must be in their follicular phase during the duration of the study period (i.e. baseline to visit 3)

4. BMI 25-34.9 ±1 kg/m2

5. Stable weight defined as less than 5kg (approx. 11lbs) gained or lost in the past 3 months

6. Sedentary subjects; defined as subjects with a desk/inactive job, not engaging in any regular sports or exercise programs either at an exercise facility or at home. Occasional activity, low intensity yoga and walking at a regular pace are acceptable.

7. Agreement to maintain current level of physical activity through the study and avoid exercising 24 hours prior to study visits

8. Agreement to adopt a diet with a 500 kcal reduction for the duration of the study period.

9. Agreement to completely avoid caffeine consumption, such as coffee, tea and soft drinks 24 hours before study visits and to limit consumption of coffee, tea and soft drinks to 2 cups per day for all other days during the study.

10. Agreement to completely avoid consumption of energy drinks for 24 hours before the screening and baseline visits and for the duration of the study.

11. Has given voluntary, written, informed consent to participate in the study

Exclusion Criteria

1. Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial
2. Immunodeficiency (i.e. HIV positive, rheumatoid arthritis, history of organ transplant)
3. Use of tobacco products and nicotine products.
4. Use of prescription, over-the-counter, or natural health products known to affect weight and/or metabolic rate within 4 weeks of randomization and during the trial
5. Unstable medical conditions
6. Uncontrolled blood pressure (i.e. systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg)
7. Type I or II diabetes, metabolic disease or any condition that in the opinion of the Qualified Investigator does not safely allow for a reduction in calorie intake
8. Any evidence of an eating disorder, such as anorexia or bulimia, or the presence of any illness that might represent a potential cause of weight loss
9. Abnormal ECG at screening
10. Clinically significant abnormal laboratory results at screening (e.g. AST and/or ALT > 2 x ULN, and/or bilirubin > 2 x ULN; serum creatinine > 1.5 x ULN)
11. Currently taking anti-psychotic medication
12. Participation in a clinical research trial within 30 days prior to randomization
13. Allergy or sensitivity to study supplement ingredients
14. Alcohol abuse (>2 standard alcoholic drinks per day)
15. Current drug abuse or drug abuse within the past 6 months
16. Use of marijuana for medical purposes
17. Individuals who are cognitively impaired and/or who are unable to give informed consent
18. Any other condition, which in the Investigator's opinion, may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
7-Keto 25mg	7-Keto 25mg	-
Placebo	Placebo	-
7-Keto 50mg	7-Keto 50mg	-

Primary Outcome Measures

Name	Time	Method
Change in resting metabolic rate	1 week: from baseline to end of study

Secondary Outcome Measures

Name	Time	Method
Change in total body fat	1 week: from baseline to end of study
Change in total body water	1 week: from baseline to end of study

Trial Locations

Locations (1)

KGK USA; 🇺🇸 Orlando, Florida, United States